IL17A and rheumatoid arthritis: Comparing the proportions of unspecifically activated, inflammatory cytokine secreting T cells between RA patients treated with either csDMARDs only or an additional or exclusive TNFi, it seemed that a csDMARD treatment is associated with reduced proportions of IFNγ- or IL-17-secreting effector, memory and TEMRA T cells.